PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
Abroad (travel likely)RecruitingPHASE2
Conditions
Primary Central Nervous System Lymphoma (PCNSL) · Secondary Central Nervous System Lymphoma (SCNSL)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China